Correction: ARISE-a prospective, non-interventional, single-arm study assessing clinical parameters associated with the use of insulin degludec/insulin aspart in patients with type 2 diabetes in realworld settings: rationale and design

Affiliations

• ¹ Department of Diabetes, Endocrinology and Metabolism, Royal North Shore Hospital, Sydney, NSW, Australia. greg.fulcher@sydney.edu.au.
• ² Northern Clinical School, University of Sydney, Sydney, NSW, Australia. greg.fulcher@sydney.edu.au.
• ³ Novo Nordisk Pharma Gulf LLC, Dubai, UAE.
• ⁴ Novo Nordisk A/S, Søborg, Denmark.
• ⁵ Department of Endocrinology, Fortis Hospital, Mohali, Punjab, India.
• ⁶ Department of Medicine, Hospital Universiti Sains Malaysia, Kota Bharu, Kelantan, Malaysia.
• ⁷ Department of Biochemistry and Molecular Biology, University of the Philippines-College of Medicine, Manila, Philippines.
• ⁸ Department of Internal Medicine, Specialised Medical Center, Riyadh, Saudi Arabia.
• ⁹ Union and Clinton Hospitals in Alberton, Gauteng, South Africa.
• ¹⁰ Department of Internal Medicine, University of the Witwatersrand, Johannesburg, South Africa.